secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orthofix Medical Inc. (OFIX)
CIK:        0000884624
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091199
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orthofix Q2 net sales $198.6M (+6% YoY); raises FY2024 guidance
---------------------------------------------------------------

- Q2 net sales $198.6M, +6% YoY; net loss $(33.4M) vs $(39.4M) prior year; EPS $(0.88).
- Non-GAAP adjusted EBITDA $16.6M (8.4% margin), +310 bps YoY from $9.9M.
- Bone Growth Therapies +12% YoY; U.S. Spine Fixation +12% YoY; Global Orthopedics +5%.
- FY2024 net sales guidance raised to $795-800M; adjusted EBITDA to $64-69M.
- Expects positive free cash flow in H2 2024; appointed four new executive team members.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/884624/000095017024091199/0000950170-24-091199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/884624/000095017024091199/ofix-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer